BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 2058083)

  • 1. Megakaryocytes in chronic myeloproliferative disorders: numerical density correlated between different entities.
    Kaloutsi V; Fritsch RS; Buhr T; Restrepo-Specht I; Widjaja W; Georgii A
    Virchows Arch A Pathol Anat Histopathol; 1991; 418(6):493-7. PubMed ID: 2058083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Planimetric analysis of megakaryocytes in the four main groups of chronic myeloproliferative disorders.
    Nafe R; Georgii A; Kaloutsi V; Fritsch RS; Choritz H
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1991; 61(2):111-6. PubMed ID: 1683718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Morphometry of megakaryocytes for supporting the histologic diagnosis of chronic myeloproliferative diseases].
    Nafe R; Holgado de Colombo S; Choritz H; Georgii A
    Pathologe; 1995 Jan; 16(1):34-40. PubMed ID: 7886012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative cytomorphology of megakaryocytes in chronic myeloproliferative disorders--analysis of planimetric and numeric characteristics by means of a knowledge based system.
    Nafe R; Kaloutsi V; Fritsch RS; Georgii A
    Exp Pathol; 1990; 40(4):213-9. PubMed ID: 2098268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Megakaryopoiesis in chronic myeloproliferative diseases. A morphometric evaluation with special emphasis on primary thrombocythemia.
    Thiele J; Funke S; Holgado S; Choritz H; Georgii A
    Anal Quant Cytol; 1984 Sep; 6(3):155-67. PubMed ID: 6594964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia.
    Michiels JJ
    Neth J Med; 1997 Aug; 51(2):57-64. PubMed ID: 9286142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The histopathology of chronic myeloproliferative diseases.
    Georgii A; Buesche G; Kreft A
    Baillieres Clin Haematol; 1998 Dec; 11(4):721-49. PubMed ID: 10640214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Density distribution and size of megakaryocytes in inflammatory reactions of the bone marrow (myelitis) and chronic myeloproliferative diseases.
    Thiele J; Holgado S; Choritz H; Georgii A
    Scand J Haematol; 1983 Oct; 31(4):329-41. PubMed ID: 6578591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic myeloproliferative disorders (CMPD).
    Burkhardt R; Bartl R; Jäger K; Frisch B; Kettner G; Mahl G; Sund M
    Pathol Res Pract; 1984 Nov; 179(2):131-86. PubMed ID: 6395125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Histopathology of Ph1-negative chronic myeloproliferative diseases].
    Georgii A; Choritz H; Büsche G; Kreft A; Buhr T
    Pathologe; 1995 Jan; 16(1):62-9. PubMed ID: 7886016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies.
    Georgii A; Buhr T; Buesche G; Kreft A; Choritz H
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():15-29. PubMed ID: 8951769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormalities of megakaryocytes in myelitis and chronic myeloproliferative diseases.
    Thiele J; Holgado S; Choritz H; Georgii A
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1982; 41(1-2):67-81. PubMed ID: 6134385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
    J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification.
    Buhr T; Georgii A; Choritz H
    Pathol Res Pract; 1993 Mar; 189(2):121-32. PubMed ID: 8321741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence from molecular genetic and cytogenetic analyses that bone marrow histopathology is reliable in the diagnosis of chronic myeloproliferative disorders.
    Werner M; Kaloutsi V; Kausche F; Buhr T; Georgii A
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1993; 63(4):199-204. PubMed ID: 8099457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
    Macavei I; Galatâr N
    Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathology of the myeloproliferative diseases.
    George TI; Arber DA
    Hematol Oncol Clin North Am; 2003 Oct; 17(5):1101-27. PubMed ID: 14560777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular detection of c-mpl thrombopoietin receptor gene expression in chronic myeloproliferative disorders.
    Duensing S; Duensing A; Meran JG; Kreft A; Büsche G; Ganser A; Georgii A
    Mol Pathol; 1999 Jun; 52(3):146-50. PubMed ID: 10621836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential of bone marrow biopsy in chronic myeloproliferative disorders (MPD).
    Bartl R; Frisch B; Wilmanns W
    Eur J Haematol; 1993 Jan; 50(1):41-52. PubMed ID: 8436214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.